Evidence map›Paper›PMID 35312853›Full record

ArticleDiscover oncology2022

Mapping human papillomavirus, Epstein-Barr virus, cytomegalovirus, adenovirus, and p16 in laryngeal cancer.

Alexandra Schindele, Anna Holm, Karin Nylander, Annika Allard, Katarina Olofsson

Open access · goldAbstract read
In one paragraph

Article in Discover oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. p16Infectious agents and cancer · 2023
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alexandra SchindeleDepartment of Clinical Sciences, Otorhinolaryngology, ÖNH-Kliniken Östersunds Sjukhus, Umeå University, 831 83, Östersund, Sweden. alexandra.schindele@umu.se.ORCID http://orcid.org/0000-0003-0007-8716
Anna HolmDepartment of Clinical Sciences, Otorhinolaryngology, ÖNH-Kliniken Östersunds Sjukhus, Umeå University, 831 83, Östersund, Sweden.ORCID http://orcid.org/0000-0003-3522-1842
Karin NylanderDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0002-4831-4100
Annika AllardDepartment of Clinical Microbiology, Clinical Virology, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0001-6949-1213
Katarina OlofssonDepartment of Clinical Sciences, Otorhinolaryngology, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0002-0649-3825
Umeå University · SEÖstersunds Hospital · SE

Funding

Cancer Research Foundation Northern Sweden LP 16-2020FoU-enheten, Region Jämtland Härjedalen JLL-939740Region Västerbotten RV938896
6 · The paper itself

Abstract

purposeApart from tobacco and alcohol, viral infections are proposed as risk factors for laryngeal cancer. The occurrence of oncogenic viruses including human papilloma virus (HPV) and Epstein-Barr virus (EBV), in laryngeal squamous cell carcinoma (LSCC) varies in the world. Carcinogenesis is a multi-step process, and the role of viruses in LSCC progression has not been clarified. We aimed to analyze the presence and co-expression of HPV, EBV, human cytomegalovirus (HCMV) and human adenovirus (HAdV) in LSCC. We also investigated if p16 can act as surrogate marker for HPV in LSCC.

methodsCombined PCR/microarrays (PapilloCheck®) were used for detection and genotyping of HPV DNA, real-time PCR for EBV, HCMV and HAdV DNA detection, and EBER in situ hybridization (EBER-ISH) for EBV detection in tissue from 78 LSCC patients. Additionally, we analyzed p16 expression with immunohistochemistry.

resultsThirty-three percent (26/78) of LSCC tumor samples were EBV positive, 9% (7/78) HCMV positive and 4% (3/78) HAdV positive. Due to DNA fragmentation, 45 samples could not be analyzed with PapilloCheck®; 9% of the remaining (3/33) were high-risk HPV16 positive and also over-expressed p16. A total of 14% (11/78) of the samples over-expressed p16.

conclusionThese findings present a mapping of HPV, EBV, HCMV and HAdV, including the HPV surrogate marker p16, in LSCC in this cohort. Except for EBV, which was detected in a third of the samples, data show viral infection to be uncommon, and that p16 does not appear to be a specific surrogate marker for high-risk HPV infection in LSCC.

Identifiers

PMID35312853
PMCPMC8938541
OpenAlexW4221038923

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.